BioXcel Therapeutics, Inc. (BTAI)
NASDAQ: BTAI · Real-Time Price · USD
3.110
-0.280 (-8.26%)
At close: Sep 12, 2025, 4:00 PM EDT
3.170
+0.060 (1.93%)
After-hours: Sep 12, 2025, 7:58 PM EDT
BioXcel Therapeutics Employees
BioXcel Therapeutics had 37 employees as of December 31, 2024. The number of employees decreased by 37 or -50.00% compared to the previous year.
Employees
37
Change (1Y)
-37
Growth (1Y)
-50.00%
Revenue / Employee
$23,459
Profits / Employee
-$1,377,027
Market Cap
45.27M
Employees Chart
Employees History
| Date | Employees | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 37 | -37 | -50.00% |
| Dec 31, 2023 | 74 | -109 | -59.56% |
| Dec 31, 2022 | 183 | 94 | 105.62% |
| Dec 31, 2021 | 89 | 39 | 78.00% |
| Dec 31, 2020 | 50 | 26 | 108.33% |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
| Company Name | Employees |
|---|---|
| UnitedHealth Group | 400,000 |
| Johnson & Johnson | 138,100 |
| Thermo Fisher Scientific | 125,000 |
| Abbott Laboratories | 114,000 |
| AstraZeneca | 92,900 |
| Novo Nordisk | 77,349 |
| Novartis AG | 75,883 |
| Merck & Co. | 75,000 |
BTAI News
- 2 days ago - BioXcel Therapeutics, Inc. (BTAI) Discuses On SERENITY At-Home Pivotal Phase 3 Safety Trial Results Call (Transcript) - Seeking Alpha
- 2 days ago - BioXcel Drug Calms Agitation At Home For Schizophrenia, Bipolar Patients - Benzinga
- 3 days ago - BioXcel Therapeutics Reports Positive Topline Exploratory Efficacy Data from SERENITY At-Home Pivotal Phase 3 Safety Trial for Agitation Associated with Bipolar Disorders or Schizophrenia - GlobeNewsWire
- 9 days ago - BioXcel Therapeutics to Present at the H.C. Wainwright 27th Annual Global Investment Conference - GlobeNewsWire
- 17 days ago - BioXcel Seeks FDA Label Expansion For Schizophrenia Treatment - Benzinga
- 17 days ago - UPDATE -- BioXcel Therapeutics Announces SERENITY At-Home Pivotal Phase 3 Safety Trial Met its Primary Endpoint in Support of sNDA Submission for Label Expansion of IGALMI® - GlobeNewsWire
- 17 days ago - BioXcel's agitation drug meets main goal in at-home study - Reuters
- 17 days ago - BioXcel Therapeutics Announces SERENITY At-Home Pivotal Phase 3 Safety Trial Met its Primary Endpoint in Support of sNDA Submission for Label Expansion of IGALMI® - GlobeNewsWire